001     143556
005     20240229112557.0
024 7 _ |a 10.1038/s41423-018-0003-5
|2 doi
024 7 _ |a pmid:29568119
|2 pmid
024 7 _ |a 1672-7681
|2 ISSN
024 7 _ |a 2042-0226
|2 ISSN
024 7 _ |a altmetric:35104214
|2 altmetric
037 _ _ |a DKFZ-2019-01137
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Carrasco, Kevin
|b 0
245 _ _ |a TREM-1 multimerization is essential for its activation on monocytes and neutrophils.
260 _ _ |a London [u.a.]
|c 2019
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1557737406_12867
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The triggering receptor expressed on myeloid cells-1 (TREM-1) is a receptor expressed on innate immune cells. By promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptors (TLRs), TREM-1 has been characterized as a major player in the pathophysiology of acute and chronic inflammatory diseases, such as septic shock, myocardial infarction, atherosclerosis, and inflammatory bowel diseases. However, the molecular events leading to the activation of TREM-1 in innate immune cells remain unknown. Here, we show that TREM-1 is activated by multimerization and that the levels of intracellular Ca2+ release, reactive oxygen species, and cytokine production correlate with the degree of TREM-1 aggregation. TREM-1 activation on primary human monocytes by LPS required a two-step process consisting of upregulation followed by clustering of TREM-1 at the cell surface, in contrast to primary human neutrophils, where LPS induced a rapid cell membrane reorganization of TREM-1, which confirmed that TREM-1 is regulated differently in primary human neutrophils and monocytes. In addition, we show that the ectodomain of TREM-1 is able to homooligomerize in a concentration-dependent manner, which suggests that the clustering of TREM-1 on the membrane promotes its oligomerization. We further show that the adapter protein DAP12 stabilizes TREM-1 surface expression and multimerization. TREM-1 multimerization at the cell surface is also mediated by its endogenous ligand, a conclusion supported by the ability of the TREM-1 inhibitor LR12 to limit TREM-1 multimerization. These results provide evidence for ligand-induced, receptor-mediated dimerization of TREM-1. Collectively, our findings uncover the mechanisms necessary for TREM-1 activation in monocytes and neutrophils.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Boufenzer, Amir
|b 1
700 1 _ |a Jolly, Lucie
|b 2
700 1 _ |a Le Cordier, Helene
|b 3
700 1 _ |a Wang, Guanbo
|b 4
700 1 _ |a Heck, Albert Jr
|b 5
700 1 _ |a Cerwenka, Adelheid
|0 P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f
|b 6
|u dkfz
700 1 _ |a Vinolo, Emilie
|b 7
700 1 _ |a Nazabal, Alexis
|b 8
700 1 _ |a Kriznik, Alexandre
|b 9
700 1 _ |a Launay, Pierre
|b 10
700 1 _ |a Gibot, Sebastien
|b 11
700 1 _ |a Derive, Marc
|b 12
773 _ _ |a 10.1038/s41423-018-0003-5
|g Vol. 16, no. 5, p. 460 - 472
|0 PERI:(DE-600)2219471-X
|n 5
|p 460 - 472
|t Cellular & molecular immunology
|v 16
|y 2019
|x 2042-0226
909 C O |o oai:inrepo02.dkfz.de:143556
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|2 G:(DE-HGF)POF3-300
|v Tumor immunology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL MOL IMMUNOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL MOL IMMUNOL : 2017
920 1 _ |0 I:(DE-He78)D080-20160331
|k D080
|l Nachwuchsgruppe Angeborene Immunität
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D080-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21